Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.65%
SPX
+0.41%
IXIC
-0.18%
FTSE
+0.43%
N225
0.00%
AXJO
+0.56%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

GKOS is now overvalued and could go down -47%

Jan 29, 2025, 1:00 PM
-25.84%
What does GKOS do
Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
Based on our analysis, Glaukos Corporation has received a rating of 1 out of 5 stars, indicating it is currently considered overvalued. Several key financial ratios demonstrate areas where Glaukos lags behind its sector peers, raising concerns about its investment attractiveness. One critical metric is the Price-to-Book (PB) Ratio, which stands at 8.40 compared to the sector average of 2.72. A higher PB ratio suggests that investors are paying significantly more for the company's assets relative to its book value, raising questions about the sustainability of such valuations. Additionally, Glaukos exhibits a Net Profit Margin of -42.79, which, while less negative than the sector's -145.98, still indicates the company is not generating profit from its revenues. This negative margin reflects ongoing challenges in achieving profitability, which can deter potential investors. The Return on Equity (ROE) Ratio is another concerning factor, with Glaukos reporting -29.16 versus the sector's -74.58. Although Glaukos's performance is better than the sector average, the negative return suggests inefficiencies in generating returns for shareholders. Lastly, the Return on Assets Ratio stands at -14.32 compared to the sector's -48.38, indicating that while Glaukos is performing better than its sector peers, it is still not effectively utilizing its assets to generate profits. This combination of high valuation metrics and negative profitability indicators suggests that Glaukos may not be a compelling investment opportunity at this time. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!